Skip to main content
. Author manuscript; available in PMC: 2014 Jul 14.
Published in final edited form as: Toxicol Pathol. 2012 Nov 28;41(5):744–760. doi: 10.1177/0192623312464308

Figure 11.

Figure 11

Cholangiocarcinoma. Immunolabelling for TGF-β1 (brown), hematoxylin counterstain. Neoplastic cholangiocytes display strong cytoplasmic immunoreactivity for TGF-β1. 60X bar = 30um.